Diabetic Retinopathy Market Report 2025

The diabetic retinopathy market size has grown strongly in recent years. It will grow from $8.61 billion in 2024 to $9.29 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to aging population, increasing prevalence of diabetes, growing awareness about diabetic retinopathy, improved healthcare infrastructure, rising healthcare expenditure.

The diabetic retinopathy market size is expected to see strong growth in the next few years. It will grow to $12.56 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to personalized medicine approaches, expansion of telemedicine services, development of novel therapeutic interventions, adoption of point-of-care testing, remote patient monitoring. Major trends in the forecast period include precision medicine in diabetic retinopathy treatment, increased focus on early detection and prevention, teleophthalmology services growth, rise in gene therapy research, continuous advancements in retinal imaging technology.

The increasing prevalence of diabetes is expected to drive the growth of the diabetic retinopathy market in the future. Diabetes is a chronic metabolic disease characterized by high blood glucose levels. This rise in diabetes prevalence is largely influenced by factors such as overweight, obesity, genetics, and physical inactivity. High blood sugar levels can damage the retina, the part of the eye responsible for detecting light and sending signals to the brain through a nerve at the back of the eye. For example, a report from the Office for Health Improvement and Disparities, a UK government department, indicated that from March 2022 to March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, while type 2 diabetes saw a 21% rise. Additionally, the proportion of people achieving target HbA1c levels reached 37.9%, the highest recorded by the National Diabetes Audit. Thus, the growing prevalence of diabetes is significantly contributing to the expansion of the diabetic retinopathy market.

The increasing proportion of aging individuals is anticipated to drive the growth of the diabetic retinopathy market in the future. Aging individuals refer to those who are progressing in age and experiencing the effects of aging. This process is associated with a heightened susceptibility to chronic conditions, such as diabetes, which raises the risk and enlarges the population vulnerable to diabetic retinopathy. For instance, a report from the World Health Organization, a Switzerland-based agency, indicated that by 2050, 80% of older individuals are expected to live in low- and middle-income countries. By 2030, one in six people worldwide will be aged 60 years or older, significantly increasing the proportion of the population in this age group. Furthermore, the global population of individuals aged 60 and older is projected to double by 2050, reaching 2.1 billion. Therefore, the growing proportion of aging individuals is contributing to the expansion of the diabetic retinopathy market.

Technological advancements represent a prominent trend gaining traction in the diabetic retinopathy market. Major companies within this market are embracing innovative technologies to maintain their competitive standing. For instance, in July 2022, Baxter International Inc., a US-based healthcare company, introduced the Welch Allyn RetinaVue 100 Imager PRO in South Korea. These cutting-edge technologies aim to facilitate the detection of diabetic retinopathy in primary care settings, streamlining the process for annual diabetic retinal exams (DREs) during routine primary care visits and enhancing patient compliance.

Companies operating in the diabetic retinopathy market are strategically entering partnerships to enhance their market profitability. Collaborations in the context of diabetic retinopathy involve coordinated efforts among diverse stakeholders, including healthcare providers, researchers, pharmaceutical companies, and advocacy groups, to address challenges associated with diabetic retinopathy. For example, in October 2023, AEYE Health, a US-based provider of AI-based diagnostics for retinal imaging, joined forces with Topcon Screen, a Japan-based diabetic screening platform. Their collaboration aims to offer point-of-care screening for diabetic retinopathy using artificial intelligence, ensuring swift and precise results. This approach enables primary care clinicians to conduct diabetic retinopathy screenings directly in their clinics, reducing non-compliance risks and addressing care gaps associated with diabetic retinopathy screening through immediate and accurate assessments at the point of care.

In January 2022, Meteda, a US-based healthcare technology company, completed the acquisition of Retmarker SA for an undisclosed amount. Through this strategic move, Meteda seeks to broaden its access to periodic screening for diabetic retinopathy, utilize AI to address various diabetes-related issues, and strengthen its position in the EMEA region. Retmarker SA, based in Portugal, is an AI technology company specializing in ophthalmology, particularly focusing on retinal conditions such as diabetic retinopathy.

Major companies operating in the diabetic retinopathy market include Pfizer Inc., F-Hoffmann-La Roche Ltd., Abbvie Inc., Bayer AG, Novartis AG, Ellex Medical Lasers Ltd., Abbott Laboratories Inc., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Icon Bioscience Inc., Allergan plc., Genentech Inc., Aurobindo Pharma, Santen Pharmaceutical Co. Ltd., Carl Zeiss Meditec AG, Valeant Pharmaceuticals International Inc., Lumenis Ltd., Optos Plc., Quantel Medical SAS, NIDEK Co. Ltd., IRIDEX Corporation, Alimera Science Inc., Kowa Company Ltd., Ocular Therapeutix Inc., Aerpio Pharmaceuticals Inc., Kodiak Sciences Inc., Oxurion NV, Graybug Vision Inc., Ampio Pharmaceuticals Inc.

North America was the largest region in the diabetic retinopathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic retinopathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diabetic retinopathy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Diabetic retinopathy is a complication of diabetes that impacts the retina, the light-sensitive tissue at the back of the eye. It occurs due to damage to the blood vessels caused by prolonged high blood sugar levels. If not properly managed, this condition can lead to vision loss and even blindness, underscoring the importance of regular eye examinations for early detection and treatment.

The primary types of diabetic retinopathy include proliferative diabetic retinopathy and non-proliferative diabetic retinopathy. Proliferative diabetic retinopathy represents the advanced stage characterized by the emergence of abnormal new blood vessels on the surface of the retina. Various treatment modalities, such as anti-VEGF drugs, intraocular steroid injections, laser photocoagulation, and vitreoretinal surgery, are employed in settings such as hospitals, ambulatory surgical centers, and other healthcare facilities.

The diabetic retinopathy market research report is one of a series of new reports that provides diabetic retinopathy market statistics, including diabetic retinopathy industry global market size, regional shares, competitors with a diabetic retinopathy market share, detailed diabetic retinopathy market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic retinopathy industry. This diabetic retinopathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The diabetic retinopathy market includes revenues earned by entities by providing ophthalmologic examination, eye management and retinal imaging and monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.